Skip to content

TFF PHARMACEUTICALS, INC.: 10-Q filed 2022-08-11

What TFF PHARMACEUTICALS, INC. reported in its quarterly report filed 2022-08-11 (fiscal Q2 2022): 32 published measures, 91 facts as tagged in accession 0001213900-22-046849.

This filing

Form
10-Q (quarterly report)
Filed
2022-08-11
Fiscal period
fiscal Q2 2022
Accession
0001213900-22-046849 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TFF PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-06-3027,913,199USD
At 2021-12-3140,697,811USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-06-303,973,699USD
At 2021-12-311,960,752USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-06-3023,939,500USD
At 2022-03-3131,585,993USD
At 2021-12-3138,737,059USD
At 2021-06-3055,620,157USD
At 2021-03-3159,536,713USD
At 2020-12-3137,339,802USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-06-3020,890,253USD
At 2021-12-3133,794,672USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-8,746,325USD91
2022-01-01 to 2022-06-30-17,122,327USD181
2022-01-01 to 2022-03-31-8,376,002USD90
2021-04-01 to 2021-06-30-4,655,712USD91
2021-01-01 to 2021-06-30-12,310,287USD181
2021-01-01 to 2021-03-31-7,654,575USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-12,260,746USD181
2021-01-01 to 2021-06-30-11,481,767USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2022-04-01 to 2022-06-3028,004USD91
2022-01-01 to 2022-06-3095,439USD181
2021-04-01 to 2021-06-301,850USD91
2021-01-01 to 2021-06-3026,165USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-15,995USD181
2021-01-01 to 2021-06-3028,884,984USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-632,684USD181
2021-01-01 to 2021-06-30-600,210USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-06-30-82,440,687USD
At 2021-12-31-65,318,360USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2022-04-01 to 2022-06-3025,373,706shares91
2022-01-01 to 2022-06-3025,372,749shares181
2021-04-01 to 2021-06-3025,369,144shares91
2021-01-01 to 2021-06-3024,261,032shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-0.34USD/shares91
2022-01-01 to 2022-06-30-0.67USD/shares181
2021-04-01 to 2021-06-30-0.18USD/shares91
2021-01-01 to 2021-06-30-0.51USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-0.34USD/shares91
2022-01-01 to 2022-06-30-0.67USD/shares181
2021-04-01 to 2021-06-30-0.18USD/shares91
2021-01-01 to 2021-06-30-0.51USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2022-06-302,332,254USD
At 2021-12-311,859,860USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,195,081USD91
2022-01-01 to 2022-03-311,177,702USD90
2021-04-01 to 2021-06-30740,535USD91
2021-01-01 to 2021-03-311,030,415USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-8,772,811USD91
2022-01-01 to 2022-06-30-17,213,175USD181
2021-04-01 to 2021-06-30-5,111,327USD91
2021-01-01 to 2021-06-30-13,012,679USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-06-3025,181,730USD
At 2021-12-3138,837,951USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-06-303,827,511USD
At 2021-12-311,960,752USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-06-303,480,461USD
At 2021-12-311,493,842USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-04-01 to 2022-06-308,800,815USD91
2022-01-01 to 2022-06-3017,308,614USD181
2021-04-01 to 2021-06-305,113,177USD91
2021-01-01 to 2021-06-3013,038,844USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-04-01 to 2022-06-305,110,805USD91
2022-01-01 to 2022-06-3010,372,409USD181
2021-04-01 to 2021-06-302,762,170USD91
2021-01-01 to 2021-06-308,040,422USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-06-3025,373,818shares
At 2021-12-3125,371,781shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2022-06-3020,890,253USD
At 2021-12-3133,794,672USD
At 2021-06-3052,067,339USD
At 2020-12-3135,300,805USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-06-30106,461,934USD
At 2021-12-31104,078,968USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2022-06-30232,138USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2022-06-30225,238USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2022-06-30167,077USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2022-06-3078,003USD
At 2021-12-3111,996USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-303,690,010USD91
2022-01-01 to 2022-06-306,936,205USD181
2021-04-01 to 2021-06-302,351,007USD91
2021-01-01 to 2021-06-304,998,422USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2022-01-01 to 2022-06-30166,174USD181
2021-01-01 to 2021-06-305,980USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2022-04-01 to 2022-06-3026,486USD91
2022-01-01 to 2022-06-3090,848USD181
2021-04-01 to 2021-06-30455,615USD91
2021-01-01 to 2021-06-30702,392USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-06-301,856,851USD181
2021-01-01 to 2021-06-30213,399USD181

Inspect the source

Entity
TFF PHARMACEUTICALS, INC. / CIK 0001733413
Captured
2026-09-21T17:25:24.015Z
SEC response SHA-256
831f4629fefc666a0d697443131c6e51c7c7a82a58f012a492b81a69560d76f0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001733413.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))